JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Edgewise Therapeutics (NASDAQ:EWTX) Stock
JPMorgan Chase & Co. has increased its price target for Edgewise Therapeutics (NASDAQ:EWTX) to $60 from $53, maintaining an "overweight" rating and suggesting a 37.61% upside. Despite this positive analyst sentiment and a "Moderate Buy" consensus rating, the company recently missed quarterly EPS estimates, and insiders have sold a significant number of shares. Hedge funds, however, have either increased or initiated new positions in the stock.
Edgewise Therapeutics (EWTX) Is Up 6.6% After Wider Q2 Losses Highlight Rising Spend - Has The Bull Case Changed?
Edgewise Therapeutics (EWTX) reported wider net losses in Q2 2026 and the first half of 2026, totaling US$57.33 million and US$106.34 million respectively, indicating increased spending. Despite this, the stock rose 6.6%, suggesting investors remain focused on the company's late-stage pipeline and upcoming clinical and regulatory milestones rather than near-term losses. However, the widening losses underscore the importance of future capital raises and present a risk due to the company's reliance on external funding.
Edgewise Therapeutics (EWTX) gives CSO 65K options at $43.56
Edgewise Therapeutics (EWTX) reported that its Chief Scientific Officer, Alan J. Russell, was granted 65,000 stock options on August 12, 2026. An amended filing corrected the exercise price to $43.56 per share, reflecting the fair market value on the grant date, with an expiration date of August 12, 2036. The options will vest in monthly installments over approximately four years, contingent on Russell's continued service.
Edgewise (NASDAQ: EWTX) CBO gets 100K options vesting from 2026
Edgewise Therapeutics, Inc. reported that its Chief Business Officer, Behrad Derakhshan, was granted 100,000 stock options. An amendment corrected the exercise price to $43.56 per share, reflecting the fair market value on the grant date. These options will vest in monthly installments over 48 months starting September 12, 2026, provided Derakhshan continues his service.
Edgewise Therapeutics (EWTX) sets GC option price at $43.56
Edgewise Therapeutics reported that its General Counsel, John R. Moore, was granted a stock option for 65,000 shares of common stock. The exercise price was corrected to $43.56 per share, reflecting the fair market value on the grant date, and the options will vest monthly starting September 12, 2026, with an expiration date of August 12, 2036. This amended filing corrects a previous clerical error regarding the exercise price.
69,441 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by Persistent Asset Partners Ltd
Persistent Asset Partners Ltd recently acquired 69,441 shares of Edgewise Therapeutics (EWTX) for approximately $2.82 million, making it their 23rd largest holding. Despite some insider selling to cover tax obligations, analysts maintain a "Moderate Buy" rating with an average price target of $49.08. Edgewise Therapeutics, a clinical-stage biopharmaceutical company, reported a quarterly loss that missed estimates.
44,466 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by GSA Capital Partners LLP
GSA Capital Partners LLP recently acquired 44,466 shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) valued at approximately $1.81 million. Other institutional investors also increased their holdings, while company insiders sold shares primarily to cover tax obligations related to vested equity awards, maintaining significant ownership. Analysts generally hold a "Moderate Buy" rating for EWTX, with an average price target of $49.08, despite the company reporting a quarterly EPS miss.
Edgewise Therapeutics (EWTX) Reports Wider Losses On A Valuation That Still Looks Rich
Edgewise Therapeutics (EWTX) reported wider net losses in Q2 2026, yet its shares have seen significant price appreciation year-to-date. The company's Price-to-Book ratio of 10.7x is significantly higher than the US Pharmaceuticals sector average, indicating investors are pricing in strong future potential despite current unprofitability. While the P/B is below its direct peer group, the valuation suggests high expectations based on its pipeline, coupled with inherent risks like ongoing losses and reliance on clinical trial success.
Edgewise Therapeutics CSO Alan Russell sells $258k in stock
Edgewise Therapeutics CSO Alan Russell sold shares worth $258,042 to cover tax obligations related to RSU vesting. Despite the "sell-to-cover" transaction, he received new RSUs and stock options, increasing his potential holdings. This follows the company's recent sale of its muscular dystrophy business for up to $2.65 billion and several positive analyst outlooks, with the stock up 212% over the past year.
Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock
Edgewise Therapeutics CEO Kevin Koch sold $785,042 worth of company stock on August 12, 2026, primarily to cover tax obligations related to Restricted Stock Unit vesting. Despite the sales, Mr. Koch also acquired new shares through vesting and was granted additional RSUs and stock options. These transactions follow a significant strategic move by Edgewise Therapeutics, which completed the sale of its muscular dystrophy business for a potential $2.65 billion, leading to positive analyst ratings and raised price targets.
Edgewise Therapeutics CMO Joanne Donovan sells $412,703 in stock
Joanne M. Donovan, CMO of Edgewise Therapeutics, sold 9,441 shares totaling $412,703 in August 2026, with a portion covering tax obligations from RSU vesting and the remainder under a Rule 10b5-1 plan. These sales followed her acquisition of shares from RSU vesting and new grants of RSUs and stock options. The company recently sold its muscular dystrophy business to Servier for up to $2.65 billion and has received positive analyst ratings.
Edgewise Therapeutics CSO Alan Russell sells $258k in stock
Edgewise Therapeutics' Chief Scientific Officer, Alan J. Russell, sold 5,901 shares of company stock for $258,042, primarily to cover tax obligations from RSU vesting. Following the sale, he still holds 31,466 shares directly, along with additional RSUs and stock options. This transaction follows the company's recent sale of its muscular dystrophy business to Servier for up to $2.65 billion and updated positive analyst ratings.
Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock
Edgewise Therapeutics CEO Kevin Koch sold $785,042 worth of company stock, primarily to cover tax obligations from vested Restricted Stock Units. The sales involved 17,971 shares at prices between $43.26 and $44.33, while Koch also acquired and was granted new RSUs and stock options. These transactions follow Edgewise Therapeutics' recent sale of its muscular dystrophy business for up to $2.65 billion, which has led to positive analyst sentiment and updated price targets.
Edgewise Therapeutics (EWTX) grants 50,000 RSUs and 100,000 options to CBO
Edgewise Therapeutics reported that its Chief Business Officer, Derakhshan Behrad, received equity awards comprising 50,000 Restricted Stock Units (RSUs) and a stock option for 100,000 shares. Behrad also had 5,781 and 7,500 RSUs convert into common stock on August 12, 2026, and subsequently sold 5,100 shares to cover tax withholding obligations through a non-discretionary sell-to-cover arrangement. The new RSUs vest in four annual installments starting August 12, 2027, and the stock option vests monthly over 48 months from September 12, 2026.
RA Capital’s 7.8% Edgewise Therapeutics (EWTX) stake totals 8.39M shares
RA Capital Management, L.P. and its affiliated parties have reported a 7.8% stake in Edgewise Therapeutics, Inc. (EWTX), totaling 8,392,730 shares of common stock. This ownership is held by RA Capital Healthcare Fund, L.P., with RA Capital having shared voting and dispositive power over these shares. The filing indicates a neutral impact and sentiment regarding this amended passive investment disclosure.
Edgewise Therapeutics (NASDAQ:EWTX) CMO Sells 6,522 Shares
Edgewise Therapeutics CMO Joanne Donovan recently sold 6,522 shares of EWTX stock for $285,989.70 to cover tax withholding obligations on vested equity awards, reducing her holdings by 36.1%. Despite this insider sale and a quarterly earnings miss, the company's shares rose 2.3%, and analysts maintain a "Moderate Buy" rating with a consensus price target of $49.08. Major institutional investors, including BlackRock Inc., have also increased their positions in the company.
Insider Selling: Edgewise Therapeutics (NASDAQ:EWTX) Insider Sells 5,901 Shares
Edgewise Therapeutics (NASDAQ:EWTX) insider Alan Russell sold 5,901 shares of the company's stock on August 12th, 2026, totaling approximately $258,051. This sale was conducted to cover tax withholding obligations related to vested equity awards. Despite this insider selling, analysts maintain a "Moderate Buy" consensus rating for EWTX, with an average price target of $49.08, and major institutional investors have recently increased their holdings.
Edgewise Therapeutics (NASDAQ:EWTX) General Counsel Sells $219,801.12 in Stock
Edgewise Therapeutics General Counsel John Moore sold 5,016 shares of EWTX stock worth $219,801.12 to cover tax withholding obligations from vested equity awards, reducing his direct ownership by 22.08%. The company's stock is trading near its 52-week high, and despite missing recent earnings expectations, analysts maintain a "Moderate Buy" consensus rating with an average price target of $49.08.
Edgewise Therapeutics (EWTX) CSO gets 97,500-share equity awards, sells shares for taxes
Edgewise Therapeutics' Chief Scientific Officer, Alan J. Russell, reported equity transactions on August 12, 2026, which included exercising Restricted Stock Units and selling 5,901 shares to cover tax withholding obligations. Additionally, Russell received new equity awards comprising 32,500 RSUs and a stock option for 65,000 shares, with specified vesting schedules. These transactions highlight routine insider compensation activities at the company.
Edgewise Therapeutics (EWTX) grants CFO 24,375 RSUs and 48,750-share option
Edgewise Therapeutics (EWTX) has granted its CFO, Michael Nofi, 24,375 Restricted Stock Units (RSUs) and an option for 48,750 shares of common stock. The RSUs vest in four equal annual installments starting August 12, 2027, and the stock options vest monthly over 48 months beginning September 12, 2026, both contingent on his continued service. These equity awards aim to align the CFO's compensation with the company's long-term performance and retain his services.
Bank of America Corp DE Decreases Position in Edgewise Therapeutics, Inc. $EWTX
Bank of America Corp DE reduced its stake in Edgewise Therapeutics (NASDAQ:EWTX) by 10% in the first quarter, selling 147,437 shares but still retaining 1.33 million shares valued at $41.8 million. Despite this reduction, other institutional investors like Janus Henderson and UBS Group increased their holdings. Edgewise Therapeutics shares opened at $43.18, and analysts maintain a "Moderate Buy" rating with a $49.08 average price target, even though the company missed its latest quarterly EPS estimate.
Edgewise Therapeutics, Inc. SEC Filing (Aug 13, 2026)
Edgewise Therapeutics, Inc. (EWTX) filed a Form 144 with the SEC on August 13, 2026, indicating a proposed sale of securities. The filing details the sale of 2,919 shares of common stock with an aggregate market value of $127,151.64 by an individual who acquired these shares as Restricted Stock Units on August 12, 2025. This neutral filing, processed by Rhea-AI, provides transparency into insider stock sales.
EWTX Maintains Neutral Rating - Price Target Raised to $36.00 by Goldman Sachs
Goldman Sachs has maintained a Neutral rating on Edgewise Therapeutics (EWTX) but increased its price target from $32.00 to $36.00. Despite the raised price target, the company's GF Score™ of 28/100, indicating financial challenges, and significant insider selling, suggest a cautious approach for investors. Edgewise Therapeutics focuses on developing treatments for muscular dystrophies and cardiac conditions, but profitability remains a concern.
Edgewise Therapeutics, Inc. $EWTX Shares Acquired by California State Teachers Retirement System
The California State Teachers Retirement System increased its stake in Edgewise Therapeutics (NASDAQ:EWTX) by 45.7% in the first quarter, acquiring an additional 23,027 shares and bringing its total holdings to 73,419 shares valued at approximately $2.3 million. Despite the company missing its latest earnings estimate and an insider selling a significant number of shares, analysts maintain a "Moderate Buy" rating with a target price of $48.75. Edgewise Therapeutics, a clinical-stage biopharmaceutical company, opened at $44.58 per share, up 2.4%, with a market capitalization of $4.84 billion.
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by Brokerages
Edgewise Therapeutics (NASDAQ:EWTX) has received a "Moderate Buy" consensus rating from eleven research firms, with an average 12-month price target of $48.75. The company recently reported a quarterly loss of $0.53 per share, missing consensus estimates, and insider Alan J. Russell sold a significant portion of his shares. The stock has seen various analyst price target adjustments, and institutional investors have been modifying their holdings.
Edgewise Therapeutics stock hits all-time high at 43.96 USD
Edgewise Therapeutics (EWTX) stock reached an all-time high of $43.96, currently trading at $44.17 with a market capitalization of $4.66 billion, reflecting a 231% increase over the past year. Despite this surge, InvestingPro data suggests the stock may be overvalued relative to its Fair Value. Recent analyst updates from RBC Capital, Goldman Sachs, Truist Securities, Leerink, and Guggenheim have set price targets ranging from $32 to $59, citing positive clinical trial results for EDG-7500 and the planned sale of its muscular dystrophy business unit.
Edgewise Therapeutics, Inc. (EWTX) stock price, news, quote and history
This page provides a comprehensive overview of Edgewise Therapeutics, Inc. (EWTX), including its current stock price, financial summary, historical data, and recent news. The company is a biopharmaceutical firm focused on developing therapies for muscle disorders, with lead product candidates like sevasemten for muscular dystrophy and EDG-7500 for hypertrophic cardiomyopathy. Recent news highlights include Q2 2026 financial results, the sale of its sevasemten muscular dystrophy business for up to $2.65 billion, and positive Phase 2 trial data for EDG-7500.
Edgewise Therapeutics, Inc. Stock 12‑Month Price Target Raised to $50.46, Implies 12% Upside
Analysts have raised the average 12-month price target for Edgewise Therapeutics, Inc. (EWTX) stock to $50.46, up from $49.92, suggesting a 12% potential upside based on the Aug. 5 closing price. The consensus rating from 13 covering analysts remains a "Buy," with 11 Buy ratings and 2 Holds.
Edgewise Therapeutics 2Q 2026: Net loss $57.3M, EPS ($0.53) — 10-Q Summary
Edgewise Therapeutics reported a net loss of $57.3M, or $0.53 per diluted share, for Q2 2026, an increase from $36.1M in the prior year. The company is strategically shifting its focus to its cardiovascular pipeline after selling its muscular dystrophy asset, sevasemten, to Servier for $1.55B, which significantly boosted its liquidity. Edgewise plans to initiate Phase 3 for EDG-7500 in Q4 2026 and Phase 2 for EDG-15400 in H2 2026.
Edgewise Therapeutics Q2 net loss widens to $57.3 million
Edgewise Therapeutics (EWTX) reported a widened net loss of $57.3 million, or $0.53 per share, for Q2 2026, compared to $36.1 million in Q2 2025. This comes as the company's research and development expenses increased to $47.5 million. The report also highlights insider selling activity and varied hedge fund movements in EWTX stock.
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
Edgewise Therapeutics (Nasdaq: EWTX) announced its second-quarter 2026 financial results, highlighted by positive top-line data from its Phase 2 CIRRUS-HCM trial for EDG-7500 in hypertrophic cardiomyopathy. The company also completed the sale of sevasemten and its muscular dystrophy business to Servier for up to $2.65 billion, significantly strengthening its balance sheet and allowing it to focus on its cardiovascular pipeline, including EDG-7500 and EDG-15400. This strategic move positions Edgewise as a cardiovascular-focused biopharmaceutical company.
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
Edgewise Therapeutics announced its second-quarter 2026 financial results, highlighted by positive top-line data from its
Edgewise Therapeutics earnings up next after HCM data, Servier deal By Investing.com
Edgewise Therapeutics is set to release its second-quarter results, with analysts anticipating a loss of $0.47 per share. The company recently agreed to sell its muscular dystrophy business to Servier for $1.55 billion and announced positive Phase 2 trial results for EDG-7500 in hypertrophic cardiomyopathy, shifting investor focus to its cardiovascular pipeline. Investors will be looking for details on how the Servier proceeds will be deployed, updates on the regulatory pathway for EDG-7500, and confirmation of the Phase 3 trial timeline.
Edgewise Therapeutics gains as investors weigh cash-rich reset and cardiovascular pipeline progress
Edgewise Therapeutics (EWTX) stock increased by 16.5% due to sustained investor confidence in its financial stability and refined cardiovascular strategy, following the sale of its muscular dystrophy business for $1.55 billion upfront. This transaction is expected to fund the development of EDG-7500 through approval, reducing financing pressure. The company also anticipates reporting earnings on August 6, 2026, and plans to initiate a Phase 3 trial for EDG-7500 in hypertrophic cardiomyopathy in Q4 2026.
Enterprise value to EBIT forward of Edgewise Therapeutics, Inc. – NASDAQ:EWTX
The article focuses on the enterprise value to EBIT forward metric for Edgewise Therapeutics, Inc. (NASDAQ: EWTX). It appears to be a financial data point or a report available on the TradingView platform, specifically within the financial overview for the company.
(EWTX) Price Dynamics and Execution-Aware Positioning
The article provides a detailed analysis of Edgewise Therapeutics Inc. (NASDAQ: EWTX) using AI models, highlighting a mixed sentiment with near-term positive and mid-term weak biases
Edgewise Therapeutics Inc (EWTX) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Edgewise Therapeutics Inc (EWTX), focusing on its stock price, market capitalization, and key financial ratios like P/E, P/B, and P/CF. It notes that relevant data for these ratios have not yet been disclosed by the company. The stock closed at $41.590, up 1.84%, with a market cap of $4.42 billion.
Edgewise Therapeutics Inc (EWTX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Edgewise Therapeutics Inc (EWTX), listing major shareholders and their proportions, as well as a breakdown of shareholder types. It also provides institutional shareholding data over various quarters and lists related ETFs holding EWTX shares.
Edgewise Therapeutics Inc (EWTX) Balance Sheet
This article provides a detailed balance sheet for Edgewise Therapeutics Inc (EWTX), presenting quarterly financial data for assets, liabilities, and shareholders' equity. It covers various line items including cash, investments, fixed assets, accrued expenses, and retained earnings, allowing for an in-depth analysis of the company's financial health over multiple quarters. The data is presented with year-over-year percentage changes for each financial metric.
Edgewise Therapeutics Inc (EWTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Edgewise Therapeutics Inc (EWTX), detailing its performance based on various indicators and moving averages. It offers insights into the stock's current technical ratings, including buy, sell, and neutral signals from MACD, RSI, KDJ, and other common technical indicators. The analysis also covers moving averages (MA5 to MA200), all of which currently show buy signals for EWTX.
Edgewise Therapeutics, Inc. Revenue Breakdown – NASDAQ:EWTX
This page on TradingView.com provides financial information for Edgewise Therapeutics, Inc. (EWTX) on the Nasdaq Stock Market. It offers an overview of the company's financials, including statements, statistics, dividends, earnings, and segments. The article indicates that the market is closed, with no trades currently occurring for EWTX.
Edgewise Therapeutics Inc (EWTX) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Edgewise Therapeutics Inc (EWTX), focusing on its volatility, financial risk, and investment risk. It presents various financial metrics such as Beta, VaR, Maximum Drawdown, Volatility, Return-to-Drawdown Ratio, Skewness, Realised Volatility, and Liquidity. The data covers different timeframes, offering insights into the stock's historical performance and risk profile.
EWTX|Edgewise Therapeutics Inc|Price:40.840|Chg%:+1.550
Edgewise Therapeutics Inc. (EWTX) stock closed at $40.84, up 3.94%, with a market cap of $4.39 billion. Analysts have a "Buy" rating for EWTX, with a target price of $49.667, indicating a 26.41% upside. The company is focused on developing novel therapeutics for muscular dystrophies and other serious muscle disorders, with lead candidates in late-stage clinical trials.
Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $55
Evercore has reiterated its Buy rating on Edgewise Therapeutics (EWTX.US) and increased its price target to $55. This revision suggests continued confidence from the analyst firm in the company's prospects.
Form 4 Edgewise Therapeutics Inc For: 17 July By Investing.com
This article reports on a Form 4 filing by Edgewise Therapeutics Inc. for July 17th. It briefly mentions the company's stock symbol (EWTX) and its percentage change for the day. The core content is a very short news piece about the Form 4 filing, with the majority of the page filled with financial market data, indices, and other news headlines.
Edgewise Therapeutics director gets 16,377 options | EWTX Insider Trading
Edgewise Therapeutics director Jonathan D. Root was granted 16,377 stock options on June 5, 2026, with an exercise price of $35.59 per share and an expiration date of June 5, 2036. The options will fully vest on the earlier of June 5, 2027, or the day before the company's 2027 annual shareholder meeting. This transaction was reported in a Form 4 filing and represents a compensation-related award.
Form 4 Edgewise Therapeutics Inc For: 17 July By Investing.com
This article from Investing.com reports on a Form 4 filing for Edgewise Therapeutics Inc. dated July 17. Form 4 filings are used to disclose changes in beneficial ownership of securities by company insiders. The article also notes the stock symbol EWTX and its performance, showing a 4.11% increase.
Edgewise Therapeutics (NASDAQ: EWTX) books big gain on $1.55B sevasemten sale
Edgewise Therapeutics has completed the sale of its sevasemten muscular dystrophy program to Servier Pharmaceuticals for an upfront cash payment of $1.55 billion, with potential for an additional $1.1 billion in milestone payments, totaling up to $2.65 billion. This transaction significantly strengthens Edgewise's balance sheet, transforming its pro forma 2025 financial results from a net loss to a net income of over $1.1 billion. The company will now focus on its cardiovascular pipeline.
Boulder biotech unloads muscular dystrophy drug for up to $2.65 billion
Boulder-based Edgewise Therapeutics has sold its muscular dystrophy drug for an upfront payment of $1.55 billion, with the potential to receive an additional $1.1 billion if certain regulatory and commercial milestones are met. The company went public on Nasdaq in 2021.
Edgewise completes sale of sevasemten to Servier for $2.65B
Edgewise Therapeutics Inc. has completed the sale of sevasemten and its muscular dystrophy business to Servier for $2.65 billion, including $1.55 billion upfront and up to $1.1 billion in milestone payments. This transaction shifts Edgewise's strategic focus to cardiovascular diseases, with the upfront proceeds funding the development of EDG-7500 and other pipeline assets. The company's stock has surged 83% year-to-date and multiple analysts have recently increased their price targets citing positive trial data and the strategic sale.
